Log In
BCIQ
Print this Print this
 

PUR0400

  Manage Alerts
Collapse Summary General Information
Company Pulmatrix Inc.
DescriptionInhaled dry powder formulation of levofloxacin using Pulmatrix's iSPERSE delivery technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Pulmonary (unspecified)
Indication DetailsTreat respiratory diseases
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/16/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today